Martin Simonetti
Director/Board Member presso Curtana Pharmaceuticals, Inc.
Profilo
Martin A.
Simonetti currently works at Curtana Pharmaceuticals, Inc., as Director from 2015 and LoveMyDelta, Inc., as Director.
Mr. Simonetti also formerly worked at Viral Logic Systems Technology Corp., as President & Chief Executive Officer from 2005 to 2011, Nexgenia, Inc., as Chairman, Alexandria Real Estate Equities, Inc., as Independent Director from 2011 to 2013, Neusentis, Inc., as Independent Director in 2011, Prismic Pharmaceuticals, Inc., as Director, EpiThany, Inc., as Director, Amgen, Inc., as Vice President-Operations & Finance in 1998, Genentech, Inc., as Group Controller in 1991, and Dendreon Corp., as Chief Financial Officer, Treasurer & SVP-Finance from 1999 to 2005.
Mr. Simonetti received his Masters Business Admin degree from Santa Clara University and graduate degree from the University of California, Davis.
Posizioni attive di Martin Simonetti
| Società | Posizione | Inizio |
|---|---|---|
Curtana Pharmaceuticals, Inc.
 Curtana Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Curtana Pharmaceuticals, Inc. is a preclinical-stage biopharmaceutical company, which engages in the provision of therapies for the treatment of brain cancer. It focuses on the development of small molecule therapeutics targeting cancer stem cells in the central nervous system for the treatment of glioblastoma and other brain cancers. The company was founded by Gregory Stein in 2013 and is headquartered in Austin, TX. | Director/Board Member | 01/08/2015 |
LoveMyDelta, Inc.
 LoveMyDelta, Inc. Information Technology ServicesTechnology Services LoveMyDelta, Inc. provides technology services. The company is headquartered in Philadelphia, PA. | Director/Board Member | - |
Precedenti posizioni note di Martin Simonetti
| Società | Posizione | Fine |
|---|---|---|
| ALEXANDRIA REAL ESTATE EQUITIES, INC. | Director/Board Member | 20/05/2013 |
Neusentis, Inc.
 Neusentis, Inc. Pharmaceuticals: MajorHealth Technology Neusentis is a biopharmaceutical company, which is focused on the discovery, development and commercialization of novel orally-administered small molecule drugs that modulate ion channel targets. The company has developed an integrated technology platform that allows for the efficient discovery of drug leads. The firm is conducting research and development activities in a number of disease areas, including epilepsy, pain and inflammation. Icagen has two clinical stage programs in epilepsy and pain. The company was formerly known as Icagen, Inc. It was founded by Andre L. Lamotte and P. Kay Wagoner on November 23, 1992 and is headquartered in Durham, NC. | Director/Board Member | 27/10/2011 |
| DENDREON CORPORATION | Director of Finance/CFO | 10/06/2005 |
| AMGEN INC. | Director of Finance/CFO | 01/01/1998 |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Comptroller/Controller/Auditor | 01/01/1991 |
Formazione di Martin Simonetti
| Santa Clara University | Masters Business Admin |
| University of California, Davis | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| AMGEN INC. | Health Technology |
| ALEXANDRIA REAL ESTATE EQUITIES, INC. | Finance |
| Aziende private | 9 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Dendreon Corp.
 Dendreon Corp. Medical SpecialtiesHealth Technology Dendreon Corp. discovers, develops and commercializes novel products for the treatment of cancer. The company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy ACI product candidates designed to stimulate an immune response in a variety of tumor types. It is an exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. Dendreon was founded by Christopher S. Henney, Edgar G. Engleman and Samuel Strober in 1992 and is headquartered in Seattle, WA. | Health Technology |
Neusentis, Inc.
Neusentis, Inc. Pharmaceuticals: MajorHealth Technology Neusentis is a biopharmaceutical company, which is focused on the discovery, development and commercialization of novel orally-administered small molecule drugs that modulate ion channel targets. The company has developed an integrated technology platform that allows for the efficient discovery of drug leads. The firm is conducting research and development activities in a number of disease areas, including epilepsy, pain and inflammation. Icagen has two clinical stage programs in epilepsy and pain. The company was formerly known as Icagen, Inc. It was founded by Andre L. Lamotte and P. Kay Wagoner on November 23, 1992 and is headquartered in Durham, NC. | Health Technology |
Nexgenia, Inc.
 Nexgenia, Inc. Medical SpecialtiesHealth Technology Nexgenia, Inc. develops molecule-specific selection reagents. Its technology include polymer-protein conjugates and magnetic nanoparticles. The company was founded by James Lai and Thomas Schulte in February 2011 and is headquartered in Seattle, WA. | Health Technology |
Viral Logic Systems Technology Corp.
 Viral Logic Systems Technology Corp. Pharmaceuticals: MajorHealth Technology Viral Logic Systems Technology Corp. provides pharmaceutical products and services. It develops treatments for autoimmune, inflammatory diseases and disorders. The company was founded by Steven R. Wiley and Craig A. Smith in 2004 and headquartered in Seattle, WA. | Health Technology |
Prismic Pharmaceuticals, Inc.
 Prismic Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prismic Pharmaceuticals, Inc. engages in the research and development of prescription drugs for kidney disease, mental health, and chronic pain. It also offers medical foods for patients with chronic kidney disease, and depression and bipolar disorder. The company was founded by Zachary Dutton, Danilo Casadei Massari, and Peter J. Moriarty in 2011 and is headquartered in Worcester, MA. | Health Technology |
EpiThany, Inc.
 EpiThany, Inc. Miscellaneous Commercial ServicesCommercial Services EpiThany, Inc. operates as clinical-stage biotechnology company. The firm develops therapeutic vaccines for a variety of solid tumours. The company was founded by William Watt and Mary Nora Disis in 2014 and is headquartered in Seattle, WA. | Commercial Services |
Curtana Pharmaceuticals, Inc.
Curtana Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Curtana Pharmaceuticals, Inc. is a preclinical-stage biopharmaceutical company, which engages in the provision of therapies for the treatment of brain cancer. It focuses on the development of small molecule therapeutics targeting cancer stem cells in the central nervous system for the treatment of glioblastoma and other brain cancers. The company was founded by Gregory Stein in 2013 and is headquartered in Austin, TX. | Health Technology |
LoveMyDelta, Inc.
LoveMyDelta, Inc. Information Technology ServicesTechnology Services LoveMyDelta, Inc. provides technology services. The company is headquartered in Philadelphia, PA. | Technology Services |
- Borsa valori
- Insiders
- Martin Simonetti
